多西他赛联合顺铂治疗晚期食管癌的临床观察

目的:观察多西他赛(DOC)联合顺铂(DDP)治疗初治及复治晚期食管癌患者的客观疗效和不良反应。方法:应用TP方案:DOC 75 mg.m-2,静脉滴注,d1;DDP 30 mg.m-2,d1～8,静脉滴注。初治组28例,复治组32例,其中食管鳞癌56例,食管低分化癌3例,食管腺鳞癌1例,均为Ⅳ期患者,每例患者接受2个周期以上方可评价疗效。结果:60例患者均可评价疗效和不良反应,初治组有效率为50.0%(14/28),疾病控制率为67.9%(19/28),中位疾病进展时间(TTP)为4.9个月。复治组有效率为25.0%(8/32),疾病控制率为62.5%(20/32),中位TTP为4.7个月。2组的有效率比较,差异有统计学意义(P<0.05),2组的中位TTP比较,差异无统计学意义(P>0.05)。主要不良反应为骨髓抑制、消化道反应及脱发。结论:DOC联合DDP是治疗初治与复治晚期食管癌的有效方案,初治者可显著提高疗效,不良反应均可耐受。

Docetaxel Plus Cisplatin for Patients with Advanced Esophageal Cancer:A Clinical Observation

OBJECTIVE: To evaluate the efficacy and toxicity of docetaxel(DOC) plus cisplatin(DDP) in initial treatment or retreatment of patients with advanced esophageal cancer.METHODS: A total of 60 patients with advanced esophageal cancer(stage Ⅳ) including 56 cases of squamous cancer,3 cases of poorly differentiated cancer and 1 case of squamous cancer were enrolled with 28 in initial treatment group and 32 in retreatment group.All patients were treated with TP regimen,i.e.docetaxel(75 mg·m-2) on day 1 plus DDP(30 mg·m-2) from day 1 to day 8 all by i.v drip infusion.After treatment of at least 2 cycles,the efficacy was evaluated.RESULTS: Efficacy and safety evaluation could be performed in all the 60 patients.In the initial treatment group vs.retreatment group,the effective rate was 50.0%(14/28) vs.25.0%(8/32)(P<0.05);the rate of disease control was 67.9%(19/28) vs.62.5%(20/ 32),and the median time to progression(TTP) was 4.9 months vs.4.7 months(P>0.05).The major adverse reactions included bone marrow suppression,reactions of digestive tract and alopecia.CONCLUSION: Docetaxel(DOC) in combination with cisplatin(DDP) was proved to be an effective regimen with remarkably improved efficacy and tolerable toxicity in both initial treatment and retreatment of patients with advanced esophageal cancer.